Immunodeficiency Virus 1 - Bibliography


Abstract image
Abstract image

Please help keeping these websites open for everybody as long as possible


Human Immunodeficiency Virus 1



  1. Hamlyn E, Jones V, Porter K, Fidler S. Antiretroviral treatment of primary HIV infection to reduce onward transmission. Curr Opin HIV AIDS. 2010 Jul;5(4):283-90.
  2. Siegfried N, Uthman OA, Rutherford GW.. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Virology. 2010 Feb 20;397(2):255-9.
  3. Barré-Sinoussi F. HIV: a discovery opening the road to novel scientific knowledge and global health improvement. Virology. 2010 Feb 20;397(2):255-9.
  4. Montagnier L. 25 years after HIV discovery: prospects for cure and vaccine. Virology. 2010 Feb 20;397(2):248-54.
  5. Montagnier L. 25 years after HIV discovery: prospects for cure and vaccine. Virology. 2010 Feb 20;397(2):248-54.
  6. Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V. Resistance to novel drug classes. Curr Opin HIV AIDS. 2009 Nov;4(6):531-7.
  7. McKinnell JA, Saag MS. Novel drug classes: entry inhibitors enfuvirtide, chemokine (C-C motif) receptor 5 antagonists. Curr Opin HIV AIDS. 2009 Nov;4(6):513-7.
  8. Arhel N, Kirchhoff F. Host proteins involved in HIV infection: new therapeutic targets. Biochim Biophys Acta. 2010 Mar;1802(3):313-21.
  9. Vrisekoop N, Mandl JN, Germain RN. Life and death as a T lymphocyte: from immune protection to HIV pathogenesis. J Biol. 2009;8(10):91.
  10. Gisselquist D. Double standards in research ethics, health-care safety, and scientific rigour allowed Africa's HIV/AIDS epidemic disasters. Int J STD AIDS. 2009 Dec;20(12):839-45.
  11. Singer EJ, Valdes-Sueiras M, Commins D, Levine A. Neurologic presentations of AIDS. Neurol Clin. 2010 Feb;28(1):253-75.
  12. Blankson JN. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res. 2010 Jan;85(1):295-302.
  13. Wirtz VJ, Forsythe S, Valencia-Mendoza A, Bautista-Arredondo S. Factors influencing global antiretroviral procurement prices. BMC Public Health. 2009 Nov 18;9 Suppl 1:S6.
  14. Fox J, Fidler S. Sexual transmission of HIV-1. Antiviral Res. 2010 Jan;85(1):276-85. Epub 2009 Oct 27.
  15. Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Res. 2010 Jan;85(1):59-74. Epub 2009 Oct 22.
  16. Dahl V, Josefsson L, Palmer S. HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res. 2010 Jan;85(1):286-94.
  17. Adamson CS, Freed EO. Novel approaches to inhibiting HIV-1 replication. Antiviral Res. 2010 Jan;85(1):119-41.
  18. Onafuwa-Nuga A, Telesnitsky A. The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev. 2009 Sep;73(3):451-80.
  19. stone MB. Anatomy of viral persistence. PLoS Pathog. 2009 Jul;5(7):e1000523.
  20. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother. 2009 Nov;64(5):910-28. Epub 2009 Sep 18.
  21. Tilton JC, Doms RW. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res. 2010 Jan;85(1):91-100.
  22. Menéndez-Arias L. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res. 2010 Jan;85(1):210-31.
  23. Woodman Z, Williamson C. HIV molecular epidemiology: transmission and adaptation to human populations. Curr Opin HIV AIDS. 2009 Jul;4(4):247-52.
  24. Motsinger-Reif AA. Discussion of a genome-wide association approach to determine HIV-1 set point in African Americans. J Infect Dis. 2010 Apr 15;201(8):1118-20.
  25. Ellis RJ, Calero P, Stockin MD. HIV infection and the central nervous system: a primer. Neuropsychol Rev. 2009 Jun;19(2):144-51.
  26. Williams KC, Burdo TH. HIV and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis. APMIS. 2009 May;117(5-6):400-12.
  27. Montal M. Vpu matchmakers as a therapeutic strategy for HIV infection.PLoS Pathog. 2009 May;5(5):e1000246.
  28. Freer G, Matteucci D. Influence of dendritic cells on viral pathogenicity. PLoS Pathog. 2009 Jul;5(7):e1000384
  29. Coleman CM, Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology. 2009 Jun 1;6:51.
  30. Fellay J. Host genetics influences on HIV type-1 disease.Antivir Ther. 2009;14(6):731-8.
  31. Medical Center Occupational Health Section. HIV and AIDS in the workplace. J Occup Environ Med. 2009 Feb;51(2):243-50.
  32. Zenner D, Tomkins S, Charlett A, Wellings K, Ncube F. HIV prone occupational exposures: epidemiology and factors associated with initiation of post-exposure prophylaxis. J Epidemiol Community Health. 2009 May;63(5):373-8.
  33. Piacentini L, Biasin M, Fenizia C, Clerici M. Genetic correlates of protection against HIV infection: the ally within. J Intern Med. 2009 Jan;265(1):110-24.
  34. Hanass-Hancock J, Nixon SA. The fields of HIV and disability: past, present and future. J Intern Med. 2009 Jan;265(1):110-24.
  35. Horenstein MG, Moontasri NJ, Cesarman E. The pathobiology of Kaposi's sarcoma: advances since the onset of the AIDS epidemic. J Cutan Pathol. 2008 Nov;35 Suppl 2:40-4.
  36. Carter CA, Ehrlich LS. Cell biology of HIV-1 infection of macrophages. Annu Rev Microbiol. 2008;62:425-43.
  37. Gupta RK, Towers GJ. A tail of Tetherin: how pandemic HIV-1 conquered the world. Cell Host Microbe. 2009 Nov 19;6(5):393-5.
  38. van Vonderen MG et al. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One. 2009 May 21;4(5):e5647.
  39. Koch AL. Stone age diseases and modern AIDS. Virol J. 2008 Aug 7;5:93.
  40. Hardon A, Desclaux A, Egrot M, Simon E, Micollier E, Kyakuwa M. Alternative medicines for AIDS in resource-poor settings: insights from exploratory anthropological studies in Asia and Africa. J Ethnobiol Ethnomed. 2008 Jul 10;4:16.
  41. Sudharshan S, Biswas J. Introduction and immunopathogenesis of acquired immune deficiency syndrome. Indian J Ophthalmol. 2008 Sep-Oct;56(5):357-62.
  42. Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol. 2008 Aug;59(2):179-206; quiz 207-8.
  43. Nakajima T, Kaur G, Mehra N, Kimura A. HIV-1/AIDS susceptibility and copy number variation in CCL3L1, a gene encoding a natural ligand for HIV-1 co-receptor CCR5. Cytogenet Genome Res. 2008;123(1-4):156-60.
  44. Saksena NK, Rodes B, Wang B, Soriano V. Elite HIV controllers: myth or reality? AIDS Rev. 2007 Oct-Dec;9(4):195-207.
  45. Méchai F, Quertainmont Y, Sahali S, Delfraissy JF, Ghosn J. Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person. J Med Virol. 2008 Jan;80(1):9-10.
  46. Sáez-Cirión A, Pancino G, Sinet M, Venet A, Lambotte O; ANRS EP36 HIV CONTROLLERS study group. HIV controllers: how do they tame the virus? Trends Immunol. 2007 Dec;28(12):532-40. Epub 2007 Nov 5.
  47. Potthoff A, Brockmeyer NH. HIV-associated Kaposi sarcoma: pathogenesis and therapy. J Dtsch Dermatol Ges. 2007 Dec;5(12):1091-4.
  48. Emau P, Jiang Y, Agy MB, Tian B, Bekele G, Tsai CC. Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention. AIDS Res Ther. 2006 Nov 28;3:29.
  49. Manavi K. A review on infection with human immunodeficiency virus. Best Pract Res Clin Obstet Gynaecol. 2006 Dec;20(6):923-40.
  50. Pai NP, Lawrence J, Reingold AL, Tulsky JP. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database Syst Rev. 2006 Jul 19;3:CD006148.
  51. Heeney JL, Dalgleish AG, Weiss RA. Origins of HIV and the evolution of resistance to AIDS. Science. 2006 Jul 28;313(5786):462-6.
  52. Levy JA. HIV pathogenesis: knowledge gained after two decades of research. Adv Dent Res. 2006 Apr 1;19(1):10-6.
  53. Telenti A, Goldstein DB. Genomics meets HIV-1. Nat Rev Microbiol. 2006 Nov;4(11):865-73.
  54. Bartholomew CF, Jones AM. Human bites: a rare risk factor for HIV transmission. AIDS. 2006 Feb 28;20(4):631-2.
  55. Telenti A. Adaptation, co-evolution, and human susceptibility to HIV-1 infection. Infect Genet Evol. 2005 Oct;5(4):327-34.
  56. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist. 2005 Jun-Jul;10(6):412-26.
  57. van Opijnen T, Berkhout B. The host environment drives HIV-1 fitness. Rev Med Virol. 2005 Jul-Aug;15(4):219-33.
  58. Nielsen MH, Pedersen FS, Kjems J. Molecular strategies to inhibit HIV-1 replication. Retrovirology. 2005 Feb 16;2:10.
  59. Nisole S, Saďb A. Early steps of retrovirus replicative cycle. Retrovirology. 2004 May 14;1:9.
  60. TakebE Y, Kusagawa S, Motomura K. Molecular epidemiology of HIV: tracking AIDS pandemic. Pediatr Int. 2004 Apr;46(2):236-44.
  61. Kourtis AP, Butera S, Ibegbu C, Beled L, Duerr A. Breast milk and HIV-1: vector of transmission or vehicle of protection? Lancet Infect Dis. 2003 Dec;3(12):786-93.
  62. Nickle DC, Shriner D, Mittler JE, Frenkel LM, Mullins JI. Importance and detection of virus reservoirs and compartments of HIV infection. Curr Opin Microbiol. 2003 Aug;6(4):410-6.
  63. Stebbing J, Patterson S, Gotch F. New insights into the immunology and evolution of HIV. Cell Res. 2003 Feb;13(1):1-7.
  64. Freed EO. HIV-1 replication. Somat Cell Mol Genet. 2001 Nov;26(1-6):13-33.
  65. Turner BG, Summers MF. Structural biology of HIV. J Mol Biol. 1999 Jan 8;285(1):1-32.
  66. Vangroenweghe D. The earliest cases of human immunodeficiency virus type 1 group M in Congo-Kinshasa, Rwanda and Burundi and the origin of acquired immune deficiency syndrome. Philos Trans R Soc Lond B Biol Sci. 2001 Jun 29;356(1410):923-5.
  67. When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009 Apr 18;373(9672):1352-63.
  68. Vangroenweghe D. The earliest cases of human immunodeficiency virus type 1 group M in Congo-Kinshasa, Rwanda and Burundi and the origin of acquired immune deficiency syndrome. Philos Trans R Soc Lond B Biol Sci. 2001 Jun 29;356(1410):923-5.
  69. Hogg R, Lima V, Sterne JA, Grabar S, Battegay M, Bonarek M, D'Arminio Monforte A, Esteve A, Gill MJ, Harris R, Justice A, Hayden A, Lampe F, Mocroft A, Mugavero MJ, Staszewski S, Wasmuth JC, van Sighem A, Kitahata M, Guest J, Egger M, May M. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008 Jul 26;372(9635):293-9.
  70. Hütter G, Schneider T, Thiel E. Transplantation of selected or transgenic blood stem cells - a future treatment for HIV/AIDS? J Int AIDS Soc. 2009 Jun 28;12(1):10.
  71. Vahlne A. A historical reflection on the discovery of human retroviruses. Retrovirology. 2009 May 1;6:40.
  72. Lewden C et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):72-7.
  73. Palella FJ Jr et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34.
  74. Gomez C, Hope TJ. The ins and outs of HIV replication. Cell Microbiol. 2005 May;7(5):621-6.
  75. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol. 2003;21:265-304.
  76. Hillis DM. AIDS. Origins of HIV. Science. 2000 Jun 9;288(5472):1757-9.
  77. Campo J, Perea MA, del Romero J, Cano J, Hernando V, Bascones A. Oral transmission of HIV, reality or fiction? An update. Oral Dis. 2006 May;12(3):219-28.
  78. Wawer MJ et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005 May 1;191(9):1403-9.
  79. Gray RH et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001 Apr 14;357(9263):1149-53.
  80. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS Res Ther. 2007 May 14;4:11.
  81. Cavarelli M, Scarlatti G. Phenotype variation in human immunodeficiency virus type 1 transmission and disease progression. Dis Markers. 2009;27(3):121-36.
  82. Goodenow MM, Collman RG. HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes. J Leukoc Biol. 2006 Nov;80(5):965-72.
  83. Mahajan VS, Pace CA, Jarolim P. Interpretation of HIV serologic testing results. Clin Chem. 2010 Oct;56(10):1523-6.
  84. Guy R et al. Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis. 2009 Dec;9(12):747-59.
  85. Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill. 2008 Sep 4;13(36). pii: 18966.
  86. Le Vu S et al. Principles and uses of HIV incidence estimation from recent infection testing--a review. Euro Surveill. 2008 Sep 4;13(36). pii: 18969.
  87. Branson BM. State of the art for diagnosis of HIV infection. Clin Infect Dis. 2007 Dec 15;45 Suppl 4:S221-5.
  88. Dwyer DE. Advances in HIV laboratory testing. N S W Public Health Bull. 2010 Mar-Apr;21(3-4):86-8.
  89. Guan M. Frequency, causes, and new challenges of indeterminate results in Western blot confirmatory testing for antibodies to human immunodeficiency virus. Clin Vaccine Immunol. 2007 Jun;14(6):649-59.
  90. Prabhu VS et al. Cost-Effectiveness of HIV Screening in STD Clinics, Emergency Departments, and Inpatient Units: A Model-Based Analysis. PLoS One. 2011;6(5):e19936.
Back to top Nemose